跳转至内容
Merck
CN
所有图片(1)

文件

安全信息

V-016

Supelco

烟酰胺 (维生素B3)标准液 CRM 溶液

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

登录查看公司和协议定价
所有图片(1)
别名:
烟酰胺, 维生素 B3, 吡啶-3-甲酰胺, 烟碱酰胺, 维生素 PP
经验公式（希尔记法）:
C6H6N2O
CAS号:
98-92-0
分子量:
122.12
Beilstein:
383619
EC 号:
200-659-6
MDL编号:
MFCD00006395
UNSPSC代码:
41116107
PubChem化学物质编号:
329828959
NACRES:
NA.24

等级

certified reference material

质量水平

300

形式

liquid

特点

Snap-N-Spike®/Snap-N-Shoot®

包装

ampule of 1 mL

制造商/商品名称

Cerilliant®

浓度

1.0 mg/mL in methanol

技术

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

mp

128-131 °C (lit.)

应用

clinical testing
clinical testing

格式

single component solution

储存温度

−20°C

SMILES字符串

NC(=O)c1cccnc1

InChI

1S/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9)

InChI key

DFPAKSUCGFBDDF-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

相关类别

一般描述

烟酰胺也称为烟碱酰胺或尼古丁酰胺。它是植物和动物食物中维生素B3的水溶性形式，并主要用作膳食补充剂。

应用

认证加标溶液适用于多种测试应用，包括通过 HPLC 对药物制剂或膳食补充剂进行的质量控制测试。
烟酰胺可作为分析参考标准品，用于通过经电喷雾质谱确证的平面色谱多重检测对功能饮料中的分析物、通过紫外-可见分光光度法和多元分析对药物制剂中的分析物进行测定。

生化/生理作用

烟酰胺是维生素B3的酰胺衍生物，是PARP抑制剂

法律信息

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

相关产品

产品编号
说明
价格

V-014

盐酸硫胺素（维生素B1）标准液 CRM 溶液, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

V-017

烟酸, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

V-019

维生素B12标准液 CRM 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

V-052

硫胺素-13C3（维生素B1-13C3） 盐酸盐 溶液, 100 μg/mL in methanol (as free base), certified reference material, ampule of 1 mL, Cerilliant®

V-055

(-)-Riboflavin-13C4,15N2 (Vitamin B2-13C4,15N2) solution, 100 μg/mL (1% ammonium acetate in 50:50 methanol:water), certified reference material, ampule of 1 mL, Cerilliant®

V-067

(−)-核黄素, 100 μg/mL (1% ammonium acetate in 50:50 methanol:water), certified reference material, ampule of 1 mL, Cerilliant®

V-063

泛酸-13C3,15N半钙盐标准液 半钙盐 溶液, 100 μg/mL (90:10 Methanol:Water, (as free acid)), certified reference material, ampule of 1 mL, Cerilliant®

V-056

核黄素5′-磷酸酯 钠盐 溶液, 100 μg/mL (50:50 Methanol:1% Ammonium Acetate in Water, (as free phosphate)), certified reference material, ampule of 1 mL

V-069

5-磷酸吡哆醛标准液 溶液, 500 μg/mL (80:20 Water:Acetonitrile), certified reference material, ampule of 1 mL, Cerilliant®

V-080

Pyridoxine-13C3 (Vitamin B6-13C3) hydrochloride solution, 100 μg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

F-087

Folic acid solution, 1 mg/mL in methanol with 0.1N NaOH, certified reference material, ampule of 1 mL, Cerilliant®

F-088

Folic acid-13C5,15N solution, 100 μg/mL (Methanol with 0.1 N NaOH), certified reference material, ampule of 1 mL, Cerilliant®

警示用语：

Danger

危险分类

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

靶器官

Eyes

WGK

WGK 2

闪点(°F)

closed cup

闪点(°C)

closed cup

法规信息

危险化学品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Simultaneous determination of riboflavin, pyridoxine, nicotinamide, caffeine and taurine in energy drinks by planar chromatography-multiple detection with confirmation by electrospray ionization mass spectrometry
Aranda M and Morlock G
Journal of Chromatography A, 1131(1-2), 253-260 (2006)
Simultaneous determination and classification of riboflavin, thiamine, nicotinamide and pyridoxine in pharmaceutical formulations, by UV-visible spectrophotometry and multivariate analysis
Lopez-de-Alba LP, et al.
Journal of the Brazilian Chemical Society, 17(4), 715-722 (2006)
Case of sorafenib-induced thyroid storm.
Sigurdis Haraldsdottir et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(16), e262-e264 (2013-04-24)
Takeshi Natori et al.
Gan to kagaku ryoho. Cancer & chemotherapy, 40(5), 635-637 (2013-07-19)
Sorafenib is an oral multi-kinase inhibitor that targets tumor growth and angiogenesis signal transduction pathways. Two global phase III trials showed that sorafenib prolonged the survival of patients with advanced hepatocellular carcinoma (HCC). Based on the positive results of these
Ning Jia et al.
Anticancer research, 33(6), 2797-2800 (2013-06-12)
Post-transplant hepatocellular carcinoma recurrence has been reported to be between 15-18% and is higher among patients with high-risk features (bilobar tumor, macrovascular invasion, or multifocality). There are no known treatments which reduce risk of recurrence post-transplant. Sorafenib is currently approved
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门